Boehringer dumps its $250M NASH drug; Bavar­i­an Nordic sells PRV for $95M; GBT inks deal with Sy­ros, gets $150M loan

→ Four years af­ter Boehringer hand­ed out a $250 mil­lion deal to get a NASH drug from Phar­max­is, they’re sweep­ing it out of the pipeline. The Ger­man phar­ma com­pa­ny not­ed to­day that the drug posed a threat of drug in­ter­ac­tions, scut­tling its as­pi­ra­tions for the pro­gram. BI 1467335 joins a long — and grow­ing — list of fail­ures in the NASH field, where drug de­vel­op­ers have been try­ing to field a ther­a­py that can bend the nee­dle on a dis­ease that af­flicts mil­lions of peo­ple world­wide.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.